Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.

Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ; Australasian Gastro-Intestinal Trials Group (AGITG).

Br J Cancer. 2013 Mar 5;108(4):771-4. doi: 10.1038/bjc.2013.41. Epub 2013 Feb 14.

2.

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L.

Eur J Cancer. 2013 Sep;49(13):2823-31. doi: 10.1016/j.ejca.2013.04.022. Epub 2013 Jun 5.

PMID:
23747051
3.

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA.

Br J Cancer. 2009 Oct 20;101(8):1261-8. doi: 10.1038/sj.bjc.6605319. Epub 2009 Sep 22.

4.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2010 Feb 2;102(3):475-81. doi: 10.1038/sj.bjc.6605522. Epub 2010 Jan 12.

5.

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P.

Eur J Cancer. 2012 Mar;48(4):510-7. doi: 10.1016/j.ejca.2011.12.005. Epub 2012 Jan 12.

PMID:
22244801
6.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators.

Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.

7.

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V.

Br J Cancer. 2016 Mar 1;114(5):505-9. doi: 10.1038/bjc.2015.440. Epub 2016 Feb 11.

8.

A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.

Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H.

Int J Clin Oncol. 2008 Apr;13(2):150-5. doi: 10.1007/s10147-007-0738-y. Epub 2008 May 8.

PMID:
18463960
9.

Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.

Hallqvist A, Wagenius G, Rylander H, Brodin O, Holmberg E, Lödén B, Ewers SB, Bergström S, Wichardt-Johansson G, Nilsson K, Ekberg L, Sederholm C, Nyman J.

Lung Cancer. 2011 Feb;71(2):166-72. doi: 10.1016/j.lungcan.2010.05.011. Epub 2010 Jun 11.

PMID:
20541833
10.

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.

Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A.

Br J Cancer. 2008 Sep 16;99(6):868-74. doi: 10.1038/sj.bjc.6604622.

11.

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.

Park SR, Kim HK, Kim CG, Choi IJ, Lee JS, Lee JH, Ryu KW, Kim YW, Bae JM, Kim NK.

Br J Cancer. 2008 Apr 22;98(8):1305-11. doi: 10.1038/sj.bjc.6604312. Epub 2008 Mar 25.

12.

[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].

Yoshida K, Wada Y, Tanabe K, Ukon K, Hihara J.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:83-6. Japanese.

PMID:
16897978
13.

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.

Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ.

Med Oncol. 2012 Sep;29(3):1707-10. doi: 10.1007/s12032-011-0093-8. Epub 2011 Oct 28.

PMID:
22033912
14.

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.

Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC.

Cancer. 2011 May 15;117(10):2050-7. doi: 10.1002/cncr.25729. Epub 2010 Nov 29.

15.

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.

Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A.

Cancer. 2010 Mar 15;116(6):1446-53. doi: 10.1002/cncr.24925.

16.

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.

Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7.

17.

Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.

Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28.

PMID:
20878159
18.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
19.

Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.

Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ.

Am J Clin Oncol. 2010 Dec;33(6):624-8. doi: 10.1097/COC.0b013e3181bead92.

PMID:
20142726
20.

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.

Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F.

Br J Cancer. 2005 Jun 20;92(12):2129-33.

Supplemental Content

Support Center